MISSISSAUGA, ON, Sept. 18, 2026 /CNW/ -- With increased demand for semaglutide, and limited supply of generic options,1,2 Novo Nordisk is confirming an established supply of Ozempic® across Canada. Ozempic® was approved by Health Canada in 2018, and there are now more than one million Canadians using semaglutide.Ozempic® (semaglutide injection) "Our company remains dedicated to supporting the ongoing health and well-being of Canadians who rely on our medicines," said Iain Graham, General Manager at Novo Nordisk. "Patients have options, and when they choose Ozempic®, we are ready to meet their needs.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.